<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264912</url>
  </required_header>
  <id_info>
    <org_study_id>05-2008</org_study_id>
    <nct_id>NCT02264912</nct_id>
  </id_info>
  <brief_title>The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry</brief_title>
  <acronym>LAPCOR</acronym>
  <official_title>The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculty Hospital Kralovske Vinohrady</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculty Hospital Kralovske Vinohrady</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ongoing LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry) registry
      was initiated in 2008 at a tertiary care cardiac center, and consecutive patients, who
      underwent intracoronary stent implantation, have been included regardless of whether
      percutaneous coronary intervention (PCI) was performed on urgent or elective basis.Patients
      were included in the registry after having signed an informed consent for participation. No
      exclusion criterion has been applied for the registry participation. Efficacy of P2Y12
      receptor antagonists has been measured by quantitative flow cytometric analysis of
      vasodilator-stimulated phosphoprotein (VASP) phosphorylation according to the manufacturer
      protocol (Platelet VASP; Diagnostica Stago, Biocytex, Asni√®res, France) on a FACScan flow
      cytometer (Becton Dickinson). Occurrence of major adverse cardiac events at 30 days, 6-months
      and one year follow up has been investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>laboratory efficacy of antiplatelet drugs measured as residual platelet reactivity, incidence of major adverse cardiovascular events and bleeding complications</measure>
    <time_frame>During the 12 months after implantation of an intracoronary stent</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Platelet Aggregation Onhibitors</condition>
  <arm_group>
    <arm_group_label>stent-PCI patients</arm_group_label>
    <description>Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiplatelet drugs - P2Y12 antagonists</intervention_name>
    <arm_group_label>stent-PCI patients</arm_group_label>
    <other_name>clopidogrel, prasugrel, ticagrelor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients were included in the registry after having signed an informed consent for
        participation. No exclusion criterion has been applied for the registry participation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients after stent PCI treated with P2Y12 antagonist

          -  Written informed consent

        Exclusion Criteria:

        - None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuzana Motovska, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty Hospital Kralovske Vinohrady</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zuzana Motovska, MD. PhD.</last_name>
    <phone>+420267163760</phone>
    <email>zuzana.motovska@fnkv.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martina Ondrakova, MD.</last_name>
    <phone>+420267163760</phone>
    <email>martina.ondrakova@fnkv.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty Hospital Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzana Motovska, MD. PhD.</last_name>
      <phone>+420267163760</phone>
      <email>zuzana.motovska@fnkv.cz</email>
    </contact>
    <contact_backup>
      <last_name>Martina Ondrakova, MD.</last_name>
      <phone>+420267163760</phone>
      <email>martina.ondrakova@fnkv.cz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <results_reference>
    <citation>Motovska Z, Odvodyova D, Fischerova M, Stepankova S, Maly M, Morawska P, Widimsky P. Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention. Am J Cardiol. 2012 Mar 1;109(5):620-3. doi: 10.1016/j.amjcard.2011.10.019. Epub 2011 Dec 10.</citation>
    <PMID>22154314</PMID>
  </results_reference>
  <results_reference>
    <citation>Motovska Z, Ondrakova M, Doktorova M, Widimsky P. Severe left ventricular systolic dysfunction is independently associated with high on-clopidogrel platelet reactivity. Am J Cardiovasc Drugs. 2014 Aug;14(4):313-8. doi: 10.1007/s40256-014-0074-3.</citation>
    <PMID>24728851</PMID>
  </results_reference>
  <results_reference>
    <citation>Ondrakova M, Knot J, Ulman J, Maly M, Motovska Z. Efficacy of P2Y12 receptor antagonists in patients with atrial fibrillation according to the CHA2DS2VASc score. Int J Cardiol. 2016 Mar 15;207:84-6. doi: 10.1016/j.ijcard.2016.01.039. Epub 2016 Jan 6.</citation>
    <PMID>26797336</PMID>
  </results_reference>
  <results_reference>
    <citation>Motovska Z, Ondrakova M, Bednar F, Knot J, Ulman J, Maly M. Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a &quot;Real World&quot; registry. Thromb Res. 2015 Jun;135(6):1093-9. doi: 10.1016/j.thromres.2015.04.014. Epub 2015 Apr 16.</citation>
    <PMID>25917561</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculty Hospital Kralovske Vinohrady</investigator_affiliation>
    <investigator_full_name>Zuzana Motovska</investigator_full_name>
    <investigator_title>Associate Professor, MD. PhD. FESC.</investigator_title>
  </responsible_party>
  <keyword>antiplatelets, percutanous coronary intervention, acute coronary syndromes, laboratory efficacy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

